Compare · BIO vs RVTY
BIO vs RVTY
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $9.68B, about 1.3x BIO ($7.56B).
- Over the past year, BIO is up 16.5% and RVTY is down 6.8% - BIO leads by 23.2 points.
- RVTY has been more active in the news (6 items in the past 4 weeks vs 3 for BIO).
- RVTY has more recent analyst coverage (18 ratings vs 11 for BIO).
- Company
- Bio-Rad Laboratories Inc.
- Revvity Inc.
- Price
- $280.15+1.84%
- $86.67+5.21%
- Market cap
- $7.56B
- $9.68B
- 1M return
- +0.48%
- -1.16%
- 1Y return
- +16.45%
- -6.77%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 1980
- News (4w)
- 3
- 6
- Recent ratings
- 11
- 18
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Latest BIO
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
- Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
- Bio-Rad Reports Third-Quarter 2025 Financial Results
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
- Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away
- Bio-Rad's Management to Participate in Upcoming Investor Conferences
Latest RVTY
- Revvity Board Declares Quarterly Dividend
- SEC Form 4 filed by Gonzales Anita
- Revvity to Present at Upcoming Investor Conferences
- Revvity downgraded by Barclays with a new price target
- Revvity to Hold Earnings Call on Tuesday, May 5, 2026
- Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows
- SEC Form 4 filed by Gonzales Anita
- SEC Form DEFA14A filed by Revvity Inc.
- SEC Form DEF 14A filed by Revvity Inc.
- Officer Gonzales Anita was granted 1,721 shares, increasing direct ownership by 42% to 5,799 units (SEC Form 4)